Endocrine Deep Dives

Эпизоды

• 
  Calcipenic and Phosphopenic Osteomalacia 13.10.2026 20мин

  Calcipenic osteomalacia arises primarily from vitamin D deficiency or resistance, or severe calcium malabsorption, resulting in impaired mineralization due to defective intestinal calcium transport and secondary hyperparathyroidism that accelerates bone resorption and hypophosphatemia. Phosphopenic osteomalacia stems from renal phosphate wasting, frequently driven by excess fibroblast growth factor 23 or hereditary tubular defects, which directly impairs hydroxyapatite crystal formation. Both entities manifest with bone pain, proximal muscle weakness, and pseudofractures, but precise differentiation via serum calcium, 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, intact parathyroid hormone, and fibroblast growth factor 23 levels is essential to direct targeted replacement or mechanism-specific antineoplastic or biological therapies.
• 
  Vitamin D Formulations 12.10.2026 20мин

  Clinical management of vitamin D deficiency requires distinguishing between native secosteroids and hydroxylated metabolites based on individual metabolic clearance and organ function. Cholecalciferol maintains superior pharmacokinetics over ergocalciferol due to higher hepatic CYP2R1 affinity, stronger vitamin D-binding protein avidity, and a longer half-life, resulting in more sustained serum 25-hydroxyvitamin D elevation. In patients with severe malabsorption, hepatic dysfunction, or acute deficiency, calcifediol offers direct intestinal absorption and rapid hepatic-independent repletion. Calcitriol and active analogs bypass renal CYP27B1 1-alpha-hydroxylation, making them strictly indicated for advanced chronic kidney disease, hypoparathyroidism, or specific metabolic bone disorders rather than nutritional deficiency.
• 
  Teprotumumab 08.10.2026 21мин

  Teprotumumab is a fully human monoclonal antibody targeting the insulin-like growth factor 1 receptor, revolutionizing the medical management of active thyroid eye disease. By blocking receptor signaling on orbital fibroblasts, it reduces inflammation, halts tissue expansion, and drives significant proptosis reduction and soft tissue improvement. Infused every three weeks for eight infusions, it offers an effective alternative to surgical decompression. Clinical monitoring must account for adverse effects, notably hyperglycemia and manageable hearing impairment.
• 
  Fragile X Premutation 07.10.2026 21мин

  Fragile X premutation carriers harbor FMR1 allele expansions containing fifty-five to two hundred CGG repeats, predisposing them to distinct clinical syndromes driven by elevated toxic messenger ribonucleic acid levels. Adult carriers face risks of fragile X-associated tremor ataxia syndrome presenting with progressive cerebellar ataxia and intention tremor, alongside fragile X-associated primary ovarian insufficiency in women. Clinical management requires genetic counseling, family screening, and targeted neurological and endocrine surveillance.
• 
  Bone Turnover Markers 06.10.2026 22мин

  PODCAST SUMMARY: Bone turnover markers provide dynamic, real-time biochemical assessment of skeletal metabolism by quantifying bone formation through serum osteocalcin and procollagen type 1 N-terminal propeptide alongside bone resorption via serum and urinary C-telopeptides. These analytes reflect rapid cellular activity months before dual-energy X-ray absorptiometry can detect significant mineral density changes, serving as essential clinical tools for monitoring antiresorptive and anabolic osteoporosis therapies, evaluating treatment adherence, and diagnosing metabolic bone disorders.
• 
  Hyperparathyroidism: Surgery vs Bisphosphonates Timing 05.10.2026 23мин

  Primary hyperparathyroidism management hinges on distinguishing symptomatic from asymptomatic disease and assessing surgical candidacy according to established biochemical and densitometric thresholds. Parathyroidectomy remains the only curative intervention, durably correcting hypercalcemia, halting bone mineral density loss, and reducing nephrolithiasis risk. Bisphosphonates offer a temporary medical alternative for severe hypercalcemia or when surgery is contraindicated, but they fail to address the underlying glandular pathology or alter the natural history of parathyroid-driven bone resorption.
• 
  Persistent Post Thyroidectomy Tingling Despite Normocalcemia 02.10.2026 27мин

  Post thyroidectomy hypocalcemia typically presents with perioral tingling and neuromuscular irritability driven by transient or permanent hypoparathyroidism. Early clinical identification relies on eliciting Chvostek and Trousseau signs alongside monitoring ionized calcium levels. Management strategies incorporate oral calcium supplementation and active vitamin D analogues to maintain safe serum thresholds and prevent tetany, while severe symptomatic drops mandate prompt intravenous calcium gluconate administration.
• 
  Real world use of Palopegteriparatide 01.10.2026 19мин

  A long-acting parathyroid hormone prodrug engineered for continuous parathyroid hormone receptor type 1 activation via physiologic autocleavage. Once-daily administration maintains stable serum calcium and phosphate levels while lowering urinary calcium excretion. This physiologic replacement reduces hypercalciuria and nephrocalcinosis risks intrinsic to conventional therapy, enabling the elimination of therapeutic active vitamin D and large oral calcium supplements.
• 
  Everything About Palopegteriparatide 30.09.2026 17мин

  Palopegteriparatide is a long-acting prodrug of parathyroid hormone designed for once-weekly subcutaneous administration in hypoparathyroidism. By providing sustained physiological systemic exposure, it normalizes serum calcium and urinary calcium excretion while eliminating the erratic fluctuations associated with conventional twice-daily short-acting teriparatide injections. Clinical trials demonstrate effective maintenance of normocalcemia independent of high-dose oral calcium and active vitamin D supplementation, significantly reducing both acute symptom burden and long-term renal complications such as nephrocalcinosis and hypercalciuria inherent to traditional management regimens.
• 
  Levothyroxine Interactions and More and More 29.09.2026 22мин

  Levothyroxine absorption is highly vulnerable to gastrointestinal disruptions and concurrent ingestions. Common culprits include calcium carbonate, ferrous sulfate, proton pump inhibitors, and fiber supplements, which bind the hormone or alter gastric pH. Co-administered agents or malabsorptive states necessitate strategic spacing of at least four hours or dosage recalibration based on free thyroxine and thyrotropin monitoring. Clinicians must systematically screen for dietary and pharmacological interferences before pursuing extensive workups for apparent refractory hypothyroidism.
• 
  Hunt for the Elusive Neuropeptides 28.09.2026 26мин

  The intense rivalry between Roger Guillemin and Andrew Schally revolutionized neuroendocrinology through the isolation of hypothalamic releasing hormones. Following their initial collaboration at Baylor University, the two researchers pursued bitter, independent competition at the Salk Institute and the New Orleans Veterans Administration. Overcoming immense biochemical barriers, their laboratories utilized industrial scale processing of slaughterhouse tissue, extracting vanishingly small concentrations of active peptides from millions of animal brains to successfully isolate thyrotropin releasing hormone and gonadotropin releasing hormone.
• 
  IPSS Case Studies 25.09.2026 25мин

  Inferior petrosal sinus sampling differentiates Cushing disease from ectopic adrenocorticotropic hormone secretion using simultaneous petrosal and peripheral venous hormone measurements. A normal pituitary magnetic resonance imaging does not exclude Cushing disease, necessitating sampling. Interpretation relies on central-to-peripheral adrenocorticotropic hormone gradients at baseline and following secretagogues like desmopressin or corticotropin-releasing hormone, utilizing a baseline gradient greater than two or a stimulated gradient greater than three. Concomitant prolactin measurement validates cannulation quality and establishes prolactin-normalized ratios to resolve ambiguous, borderline, or flat gradients, particularly in patients with cyclic hypercortisolism.
• 
  Inferior petrosal sinus sampling 24.09.2026 22мин

  Inferior petrosal sinus sampling is the diagnostic gold standard for localizing the source of adrenocorticotropic hormone dependent Cushing syndrome when pituitary imaging is non diagnostic or discordant. The procedure relies on comparing simultaneous central venous hormone concentrations from each petrosal sinus against peripheral levels, both at baseline and following administration of a secretagogue such as desmopressin or corticotropin releasing hormone. A central to peripheral gradient confirms a pituitary corticotroph source, whereas a flat gradient points toward ectopic secretion. Concomitant measurement of prolactin validates successful catheterization of the pituitary venous effluent and assists in interpreting borderline or discordant adrenocorticotropic hormone ratios.
• 
  Testing for 1-25 dihydroxy Vitamin D 23.09.2026 26мин

  Assessing nutritional vitamin D status requires measuring 25-hydroxyvitamin D, as serum 1,25-dihydroxyvitamin D is tightly regulated by parathyroid hormone, calcium, and phosphate, often remaining normal or paradoxically elevated in severe nutritional deficiency due to secondary hyperparathyroidism. Clinical ordering of 1,25-dihydroxyvitamin D must be strictly reserved for evaluating complex disorders of calcium homeostasis, granulomatous diseases, lymphomas, advanced chronic kidney disease, or rare hereditary rickets. Inappropriate ordering misleads clinical management, triggers insurance reimbursement denials, and increases low-value healthcare expenditure. Clinicians should treat 1,25-dihydroxyvitamin D exclusively as a specialized endocrine regulator rather than a screening tool for vitamin D stores.
• 
  Insulin Analogs 22.09.2026 24мин

  Modern insulin pharmacokinetics are determined by molecular engineering targeting hexamer dissociation and systemic absorption kinetics. Rapid-acting formulations incorporate amino acid substitutions and excipients to accelerate hexamer-to-monomer transition for postprandial glycemic coverage. In contrast, basal analogs utilize fatty-acid acylation to facilitate subcutaneous multi-hexamer depot formation or reversible albumin binding, extending half-lives and flattening therapeutic profiles. Mastering these structural differences enables clinicians to optimize prandial dosing flexibility, minimize hypoglycemia risks, safely execute product conversions, and guide precise perioperative glycemic regimens tailored to patient-specific metabolic demands.
• 
  Insulin Icodec 21.09.2026 21мин

  Insulin icodec, marketed as Awiqli, is a groundbreaking once-weekly basal insulin designed to simplify diabetes management by drastically reducing the number of required injections. Through its unique ability to bind to albumin, the medication maintains a long half-life of approximately eight days, providing steady glucose control for an entire week.
• 
  Thyroid Nodules and Dysphagia 18.09.2026 22мин
• 
  FHH vs Normo-hormonal PHPT 17.09.2026 22мин

  Familial hypocalciuric hypercalcemia and normohormonal primary hyperparathyroidism present significant diagnostic overlap, both manifesting with hypercalcemia alongside inappropriately non-suppressed or normal intact parathyroid hormone levels. Differentiating these entities hinges on accurate assessment of renal calcium handling. Calculating the 24-hour urinary calcium-to-creatinine clearance ratio remains the standard initial screening tool, where a ratio below 0.01 strongly suggests familial hypocalciuric hypercalcemia, whereas a ratio above 0.02 favors primary hyperparathyroidism.
• 
  Everything about Cinacalcet 16.09.2026 23мин

  Cinacalcet is a positive allosteric modulator of the parathyroid calcium-sensing receptor (CaSR) indicated for hypercalcemia in primary hyperparathyroidism (PHPT) when parathyroidectomy is unfeasible. By enhancing receptor sensitivity to ambient calcium, it suppresses parathyroid hormone (PTH) secretion, normalizing serum calcium in up to 76% of patients. Crucially, cinacalcet does not improve bone mineral density or alter urinary calcium excretion. Initiation starts at 30 mg twice daily with food, titrating every 2-4 weeks. Monitoring requires weekly serum calcium during titration, every 2 months during maintenance, and tracking CYP2D6 inhibition and hepatic impairment.
• 
  Oncocytic Thyroid Carcinoma 15.09.2026 22мин

  Oncocytic thyroid carcinoma, historically classified as a Hürthle cell variant of follicular carcinoma, represents a distinct clinical entity driven by mitochondrial DNA mutations and widespread chromosomal loss of heterozygosity. Pathologically defined by over 75 percent eosinophilic, mitochondria-dense cells, it exhibits an aggressive phenotype with heightened rates of distant metastasis and structural recurrence. Crucially, metabolic mitochondrial dysfunction leads to loss of sodium-iodide symporter expression, rendering these tumors intrinsically resistant to radioactive iodine therapy despite high fluorodeoxyglucose avidity on PET imaging. Management prioritizes complete surgical resection, with systemic kinase inhibitors indicated for progressive, refractory disease.